China Tobacco Hong Kong's 2022 Annual Report

Mar.13.2023
China Tobacco Hong Kong's 2022 Annual Report
China Tobacco Hong Kong's net profit falls 46.66% while new tobacco business sees 10% growth in 2022 fiscal year.

On March 9th, China Tobacco International HK Co. Ltd. released its annual report for the 2022 fiscal year on the Hong Kong stock exchange. According to the report, the company's net profit in 2022 decreased by 46.66% compared to the previous year. However, its new tobacco business saw a 10% increase in sales, and the company's operations in Brazil saw impressive growth.


China Tobacco Hong Kong reported a total operating income of HKD 8.324 billion (approximately RMB 7.3 billion) for the fiscal year 2022, showing a year-on-year growth of 3.23%. However, the net profit attributable to the parent company was HKD 375 million (approximately RMB 330 million), marking a significant decline of 46.66% from the previous year. The basic earnings per share were HKD 0.54.


China Tobacco Hong Kong has explained that the decline in performance is mainly due to weak sales in local cigarette markets in Southeast Asia, caused by increased tobacco taxes and the impact of the pandemic, as well as a weakened demand for tobacco leaves from customers. Additionally, there has been a reduction in suitable tobacco resources available for exportation from China.


Image source: Hong Kong Stock Exchange.


CNTC Hong Kong's new tobacco product exports increased by 47,620 thousand units YoY, accounting for a growth rate of 10%, with total export quantities being 502,390 thousand units. Revenue also increased by HKD 86 million (approximately CNY 75.3 million), resulting in a total revenue of HKD 110 million (approximately CNY 96.33 million), reflecting an 8% increase YoY. However, gross profit decreased by HKD 3.2 million (approximately CNY 2.8 million), representing an 8% decline YoY.


China Tobacco Hong Kong has attributed the growth in sales and revenue of its new tobacco products to its expansion into new markets such as the Middle East, Western Europe, and Eastern Europe. The company has also increased efforts to upgrade its products in response to changing market demands. However, the decrease in profit margin is due to increased investment in marketing resources aimed at gaining more market share.


It is worth mentioning that according to China National Tobacco Corporation Hong Kong's 2022 annual report, its business in Brazil has also grown significantly. Its non-wholly owned subsidiary, CBT, under China National Tobacco Corporation Brazil, exported 29,247 tons of tobacco products to regions outside of China, a year-on-year increase of 33%; revenue was 543 million yuan, a year-on-year increase of 73%; and gross profit was 123 million yuan, a year-on-year increase of 139%.


According to an announcement, China National Tobacco Corporation Hong Kong (CNTC Hong Kong) plans to seize the opportunity presented by the adjustment of China's domestic epidemic prevention policies to continue implementing a dual-wheel development model based on both outward and inward growth. The company will focus on promoting the development of new tobacco product export business and a recovery of cigarette export business.


Reference:


International Chinese cigarette company, limited (Hong Kong) has released their annual report as of December 31, 2022.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
UK Vape Tax Countdown: Retailer Vape HQ Estimates 100ml E-liquid Prices Could Rise From £12.99 to £39.39, While Pod Kits Increase Less Than 10%
The UK’s Vaping Products Duty (VPD), scheduled to take effect in October 2026, is prompting retailers to assess how different vape categories may be affected. UK retailer Vape HQ has estimated potential price changes under the new volume-based tax system, showing that 100ml shortfill e-liquids could see prices rise from around £12.99 to £39.39, a 203% increase, while 2ml prefilled pod vape kits could rise from £5.99 to £6.52, an increase of about 9%. The estimates highlight how a volume-based tax structure creates uneven cost impacts across product categories.
Aug.19
Australian Coalition Taskforce Calls for 80% Tobacco Tax Cut to Combat Illicit Market
Australian Coalition Taskforce Calls for 80% Tobacco Tax Cut to Combat Illicit Market
According to SGST on August 26, 2026, Australia’s Coalition Illegal Tobacco Taskforce released a report recommending an up to 80% cut in tobacco excise to reduce the appeal of the illicit tobacco market. The report claimed organised crime groups now control about 80% of Australia’s tobacco market and argued that high excise rates have widened the price gap between legal and illegal products. The recommendation remains a policy proposal and has not been adopted by the Australian government, which said its focus remains on enforcement, compliance and additional resources.
Aug.27
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China National Tobacco Corporation and several subsidiaries plan to invest a combined CNY 60 billion ($8.7 billion) in share placements by Industrial and Commercial Bank of China and Agricultural Bank of China as strategic investors. The agreements extend beyond equity investment to corporate governance, banking services and supply-chain finance. The filings also disclose 2025 data on China Tobacco’s tax and profit contributions and industry scale.
Sep.07
BAT Expands ITC Infotech Partnership Across Poland, Romania and India to Advance AI
BAT Expands ITC Infotech Partnership Across Poland, Romania and India to Advance AI
ITC Infotech has expanded its multi-year strategic technology partnership with British American Tobacco (BAT), providing technology services across Poland, Romania and India while continuing to support BAT's newly launched Future Capabilities Centre in India and existing technology hubs in Malaysia and Mexico. The companies said the agreement will focus on AI-enabled innovation, technology capability building and greater operational efficiency. The partnership also aligns with BAT's broader Fit2Win transformation programme, under which the group is expanding the use of external technology and business-services partners to simplify its global operating model.
Aug.13
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
China Tobacco Supply-Chain Leader Huabao’s Three-Way Transformation Takes Hold as Overseas Revenue Jumps 216%, Non-Flavor Businesses Reach 42.2% and the Company Expands Into Global Next-Generation Tobacco Supply Chains
Huabao’s H1 2026 results show the company advancing across three connected fronts: international expansion, entry into next-generation tobacco supply chains and diversification beyond its traditional tobacco-related base. Overseas revenue rose 216.08% to CNY 96.02 million, while non-flavor businesses reached 42.2% of total revenue. Huabao also said it had entered the supply chains of leading global tobacco customers, as its nutrition, food ingredient, fragrance and personal-care businesses gained ground in Europe, Southeast Asia, Australia and New Zealand. However, adjusted net profit increased only 2.78%, and next-generation tobacco revenue was not separately disclosed, showing that the transformation is reshaping revenue and customer exposure but has yet to translate fully into underlying earnings.
Aug.28